$LQDA

Bloch Stephen M sold $7.6M of LQDA (indirect holdings)

Bloch Stephen M sold 100,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $75.74 ($75.54–$76.18, $7.57M total) across 2 trades on 2026-06-22.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 24, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosed open-market sale provides a fresh, filing-based datapoint on insider behavior, but it does not include new guidance, trial results, or regulatory outcomes.

02

Market read

Traders may briefly reassess sentiment around LQDA based on the size of the director sale, but the filing alone is unlikely to drive a sustained repricing without accompanying fundamentals.

03

What to watch

The transaction is described as indirect holdings and does not clarify tax/estate mechanics; traders should watch for subsequent filings (additional sales/buys) and any concurrent company news.

Relevance 6/10Novelty 5/10Timing: after-hours/filing update (Form 4 filed 2026-06-24)

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp (LQDA) by director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Stephen M. Bloch sold 100,000 shares in open-market transactions on 2026-06-22 for about $7.57M total value.

Expected impact

Likely limited, short-lived impact unless follow-on selling or new company fundamentals emerge.

Evidence & confidence

The filing is a Form 4 insider transaction with disclosed sale size and price range, but it provides no new operational/financial information; also notes no 10b5-1 plan.

Market effects

Minimal; this is company-specific insider selling with no sector-wide regulatory/earnings signal.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity events; without a 10b5-1 plan, the sale still may reflect pre-existing personal needs rather than bearish expectations.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure (LQDA).

  • Stephen M. Bloch

    Director who sold 100,000 shares in open-market transactions on 2026-06-22; indirect holdings; no 10b5-1 plan stated.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient